Shire (NASDAQ:SHPG) has been assigned a $222.00 price target by Cantor Fitzgerald in a research note issued on Wednesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 67.09% from the company’s previous close.
The analysts wrote, “Shire reported 4Q17 results and provided its 2018 financial guidance this morning. The report was mixed relative to expectations. Investors that we spoke with were anticipating a strong 4Q17 with no surprises, but hoping for 2018 consensus sales and EPS that would at least bracket consensus (which did not happen).””
Several other brokerages have also recently issued reports on SHPG. ValuEngine cut Shire from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research cut Shire from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. FBR & Co started coverage on Shire in a research note on Thursday, October 19th. They issued a “buy” rating and a $201.00 price objective on the stock. Royal Bank of Canada reiterated a “buy” rating on shares of Shire in a research note on Thursday, November 16th. Finally, Liberum Capital upgraded Shire from a “hold” rating to a “buy” rating in a research note on Tuesday, November 14th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $212.50.
Shire (NASDAQ:SHPG) last released its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 EPS for the quarter, topping the consensus estimate of $3.86 by $0.12. The business had revenue of $4.15 billion during the quarter, compared to analyst estimates of $3.97 billion. Shire had a return on equity of 14.41% and a net margin of 10.95%. The company’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period last year, the business posted $3.37 earnings per share. research analysts expect that Shire will post 15 earnings per share for the current year.
Institutional investors have recently bought and sold shares of the business. SeaCrest Wealth Management LLC acquired a new stake in Shire in the fourth quarter valued at $107,000. Avestar Capital LLC purchased a new position in shares of Shire during the fourth quarter worth about $116,000. Amica Retiree Medical Trust purchased a new position in shares of Shire during the fourth quarter worth about $120,000. BB&T Investment Services Inc. grew its holdings in shares of Shire by 1,672.3% during the third quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 786 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC purchased a new position in shares of Shire during the third quarter worth about $159,000. Institutional investors own 20.74% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2018/02/14/shire-shpg-pt-set-at-222-00-by-cantor-fitzgerald.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.